Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
BEAM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.84 - $36.75
Previous CloseN/A
Volume491.48K
Average Volume (3M)1.99M
Market Cap
$2.26B
Enterprise Value$1.26B
Total Cash (Recent Filing)$281.97M
Total Debt (Recent Filing)$161.43M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
May 13, 2025EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.58
Shares Outstanding99,839,980
10 Day Avg. Volume2,869,359
30 Day Avg. Volume1,990,479
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)31.15
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit19.76
Enterprise Value/Ebitda-3.27
Forecast
1Y Price Target
$46.91Price Target Upside101.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentBeam has established clinical proof-of-concept in AATD while simultaneously validating their proprietary LNP as the foundation for their in vivo liver-targeted franchise.
Financial PerformanceBeam announced a $500M follow-on offering which extends the company’s cash runway into 2028.
Bears Say
Market CompetitionAATD is a crowded space with multiple types of treatment modalities in development, which could present competition for Beam.
Market ReactionShares are trading down after the announcement, indicating market concerns despite the positive initial data.
---
Ownership Overview
26.97% Insiders
16.69% Mutual Funds
0.09% Other Institutional Investors
31.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $20.84 and its highest was $36.75 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $2.26B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 52 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Feb 25, 2025. The company reported -$1.09 earnings per share for the quarter, beating the consensus estimate of -$1.228 by $0.138.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics does not currently pay dividends.
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.21.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 99,839,980 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.09 in its last earnings report, beating expectations of -$1.228. Following the earnings report the stock price went down -3.085%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Currently, no hedge funds are holding shares in BEAM
---
Beam Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.91 (101.33% Upside)
$46.91 (101.33% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 71%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 852.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.41%
12-Months-Change
Fundamentals
Return on Equity
-43.94%
Trailing 12-Months
Asset Growth
-24.38%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
---
BEAM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of significant advancements in Beam's clinical programs, particularly in sickle cell disease and liver genetic diseases, alongside notable challenges related to patient safety in ongoing trials. While the progress in clinical data and technology development is promising, the safety concerns related to conditioning agents are a critical issue.Read More>---
BEAM Stock 12 Month Forecast
Average Price Target
$46.91
▲(101.33% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Replimune Group
―
Verve Therapeutics
―
Best Analysts Covering BEAM
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
-5.46%
reiterated a buy rating 2 months ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -5.46% per trade.
---